CLIN.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally...

Stats
Šios dienos apimtis	1.79M
Vidutinė apimtis	1.68M
Rinkos kapitalizacija	0.00
EPS	£0.0264 ( 2020-09-29 )
Last Dividend	£5.46 ( 2021-12-02 )
Next Dividend	£0 ( N/A )
P/E	0.410
ATR14	£0 (0.00%)

Clinigen Group PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ARE.L	0.952
3USS.L	0.942
3ULS.L	0.939
XPD.L	0.936
MNZS.L	0.93
PBLT.L	0.925
GAW.L	0.91
GPH.L	0.891
IGE.L	0.878
AIBG.L	0.876

10 Labiausiai neigiamai susiję koreliacijos
YGEN.L	-0.965
DNM.L	-0.942
ECHO.L	-0.941
FRG.L	-0.932
EXR.L	-0.932
3NGL.L	-0.931
SIXH.L	-0.925
GIF.L	-0.921
VCAP.L	-0.911
MAST.L	-0.911

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Clinigen Group PLC Finansinės ataskaitos

Annual	2021
Pajamos:	£523.60M
Bruto pelnas:	£197.90M (37.80 %)
EPS:	£0.233

FY	2021
Pajamos:	£523.60M
Bruto pelnas:	£197.90M (37.80 %)
EPS:	£0.233

FY	2020
Pajamos:	£504.30M
Bruto pelnas:	£220.00M (43.62 %)
EPS:	£0.103

FY	2019
Pajamos:	£456.90M
Bruto pelnas:	£182.30M (39.90 %)
EPS:	£0.0400

Financial Reports:

No articles found.

Clinigen Group PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Clinigen Group PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.57 - good (95.68%) | Divividend Growth Potential Score: 2.52 - No dividend growth expected in the near future

Information

First Dividend	£0.600	2013-03-06
Last Dividend	£5.46	2021-12-02
Next Dividend	£0	N/A
Payout Date	2022-01-04
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	£45.62	--
Avg. Dividend % Per Year	0.20%	--
Score	3.07	--
Div. Sustainability Score	9.57
Div.Growth Potential Score	2.52
Div. Directional Score	6.04	--

Next Divdend (Est)
(2024-10-28)

£0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.07

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£5.60	0.64%
2019	£6.70	0.91%
2020	£7.61	0.83%
2021	£7.61	1.09%
2022	£0	0.00%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TMIP.L	Dividend Junior	2023-08-10	Quarterly	2	0.02%
LTHM.L	Dividend Knight	2023-08-03	Semi-Annually	33	0.87%
COD.L	Dividend Knight	2023-06-12	Annually	23	2.36%
ROOF.L	Dividend Knight	2023-08-03	Quarterly	3	1.92%
HHV.L	Dividend Knight	2023-06-29	Semi-Annually	19	3.83%
AVON.L	Dividend Junior	2023-08-10	Semi-Annually	33	1.69%
VCAP.L	Dividend Knight	2023-09-14	Semi-Annually	4	3.56%
MRCH.L	Dividend King	2023-07-06	Quarterly	53	3.07%
DLN.L	Dividend Knight	2023-09-07	Semi-Annually	32	1.77%
SHG.L	Dividend Knight	2023-11-02	Semi-Annually	4	0.91%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0579	1.500	8.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0284	1.200	9.05	10.00	[0 - 0.3]
returnOnEquityTTM	0.0679	1.500	-0.357	-0.535	[0.1 - 1]
payoutRatioTTM	0.333	-1.000	6.67	-6.67	[0 - 1]
currentRatioTTM	1.752	0.800	6.24	4.99	[1 - 3]
quickRatioTTM	0.480	0.800	-1.884	-1.507	[0.8 - 2.5]
cashRatioTTM	0.480	1.500	8.45	10.00	[0.2 - 2]
debtRatioTTM	0.393	-1.500	3.45	-5.18	[0 - 0.6]
interestCoverageTTM	5.00	1.000	9.26	9.26	[3 - 30]
operatingCashFlowPerShareTTM	0.348	2.00	9.88	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.130	2.00	9.93	10.00	[0 - 20]
debtEquityRatioTTM	0.937	-1.500	6.25	-9.38	[0 - 2.5]
grossProfitMarginTTM	0.378	1.000	7.03	7.03	[0.2 - 0.8]
operatingProfitMarginTTM	0.112	1.000	9.77	9.77	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.108	1.000	-0.511	-0.511	[0.2 - 2]
assetTurnoverTTM	0.491	0.800	-0.0576	-0.0460	[0.5 - 2]
Total Score				9.57

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.63	1.000	6.10	0	[1 - 100]
returnOnEquityTTM	0.0679	2.50	-0.229	-0.535	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.130	2.00	9.96	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.348	2.00	9.88	10.00	[0 - 30]
payoutRatioTTM	0.333	1.500	6.67	-6.67	[0 - 1]
pegRatioTTM	-48.27	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				2.52

Clinigen Group PLC

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.